news
New UK drug delivery centre to support RNA therapeutic development
To develop new lipid nanoparticle formulations for RNA therapeutic delivery technologies, CPI and partners are working to establish a new UK Intracellular Drug Delivery Centre.
List view / Grid view
University of Strathclyde
news
CPI opens £88 million manufacturing innovation centre
CPI has opened its Medicines Manufacturing Innovation Centre in Scotland to focus on efficient, sustainable manufacturing and advance medicine research.
article
Menopause, contraception, endometriosis: are women’s health issues finally being recognised?
Despite recent progress in women’s health issues, there are still many challenges women continue to face when accessing healthcare. Here, Alison Slingsby of HRA Pharma discusses the recent advancements made in the UK and where further development is required.
news
Could amphibian foam be the future of topical drug delivery?
According to researchers, amphibian foam from the nests of the túngara frog could revolutionise topical, vaginal and rectal drug delivery.
news
Pharma industry employs 5,600 people in Scotland, report says
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
news
Miniature pipe organ could improve medical image quality
Researchers have developed a miniature version of the musical instrument pipe organ that could be used to improve the quality of medical imaging...
article
NIR In-Depth Focus 2018
This In-Depth Focus on near-infrared spectroscopy considers analysis using an innovative SAR-DRM and explores advances in technology that have an application on PAT/QbD.
news
£54 million funding to transform health through data science
Health Data Research UK is awarding £30 million funding to six sites across the UK to address challenging healthcare issues through the use of data science...
article
PAT: In-Depth Focus 2014
This PAT In-Depth Focus explores current challenges posed by the slow uptake of Process Analytical Technology within the pharmaceutical and biopharmaceutical industries. The advantages of incorporating PAT into the pharmaceutical process are highlighted in two informative articles, and possible solutions to its lack of popularity surmised...
article
Chemometrics: Implementing multivariate data analysis to monitor mammalian cell culture processes
13 June 2013 | By Payal Roychoudhury, formerly AstraZeneca and Ronan O’Kennedy, Fujifilm Diosynth Biotechologies and Jim Faulkner, GlaxoSmithKline and Brian McNeil & Linda M. Harvey, University of Strathclyde
Biopharmaceutical companies are constantly evaluating new methods for mammalian cell line development that offer benefits such as shorter time lines, improved consistency, higher monoclonal antibody (mAb) production, better genetic stability and increased flexibility. Each of these advantages extends a potentially large cost benefit to companies as their recombinant protein products…
news
Strathclyde awards honorary degree to world-leading cancer researcher
15 November 2012 | By University of Strathclyde
A Nobel Prize winner has been awarded an honorary degree by the University of Strathclyde...
news
University opens £36 million facility for pharmacy and biomedical sciences
31 October 2011 | By University of Strathclyde
A pioneering research institute to drive forward the search for new and better medicines to open...
article
Polymorph screening in pharmaceutical development
19 August 2010 | By Professor Alastair J. Florence, Solid-State Research Group, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde
The majority of active pharmaceutical ingredients (APIs) are produced by crystallisation and so the phenomenon of polymorphism, whereby an organic molecule can adopt more than one crystalline form (Figure 1), is of considerable importance when trying to achieve consistent product quality during the manufacture of pharmaceutical solids and solid dosage…
article
Aseptic preparation: The weakest link is getting stronger
12 December 2009 | By Gavin Halbert, Director, Cancer Research UK Formulation Unit, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde
The manufacture of sterile products attracts the greatest regulatory scrutiny of all product types, since manufacturing failures can be fatal and manufacturers are required to utilise the most robust sterilisation method possible to limit the probability of this occurring. However, aseptic preparation, which is the last resort manufacturing method, continues…
article
Cost, knowledge and convenience: facing the facts
2 February 2006 | By Professor David Littlejohn, Head of the Department of Pure and Applied Chemistry at the University of Strathclyde, Director of CPACT at the University of Strathclyde
There can be no doubt that the FDA’s initiative on Process Analytical Technologies (PAT) has had an enormous impact on the pharmaceutical industries. However, the emergence of ’born again‘ PAT devotees in pharma companies has caused mild amusement in other industries where on-line analysis has been an integral part of…
